Ipragliflozin + Insulin
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Jul 29, 2016 โ Nov 9, 2017
NCT ID
NCT02847091About Ipragliflozin + Insulin
Ipragliflozin + Insulin is a approved stage product being developed by Astellas Pharma for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT02847091. Target conditions include Type 2 Diabetes Mellitus.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02847091 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus